HOME >> BIOLOGY >> NEWS
Two-pronged attack targeting EGF receptor hinders cancer cell growth

Hitting the epidermal growth factor receptor (EGFR) both high and low with a combination of drugs for targeted cancer therapy curbs cancer cell growth more effectively than using the drugs each by themselves, researchers from the University of Wisconsin-Madison reported in the August 1 issue of the journal Cancer Research.

EGFR drives unregulated growth in many types of cancer, and the new molecular cancer drugs, cetuximab (Erbitux, ImClone), and gefitinib (Iressa, AstraZeneca) have recently gained FDA approval as therapeutics targeted at the EGFR to inhibit cancer cell proliferation. A third EGFR inhibiting drug, and erlotinib (Tarceva, Genentech), may have FDA approval within a year.

The Wisconsin study examined the combined effect of Erbitux with either Iressa or Tarceva to control growth of head and neck, prostate, and lung cancer cell lines grown in culture, and lung cancer tumors developing in animals.

Tandem application of either Erbitux and Iressa, or Erbitux and Tarceva, proved synergistically more effective than single drug treaent at several levels.

"The combination of Erbitux with either Iressa or Tarceva inhibited cancer cell growth both in cell culture and in live animals more effectively than any of the drugs alone," said the study's senior author, Paul Harari, M.D., associate professor of human oncology, University of Wisconsin Medical School and Comprehensive Cancer Center.

"The impact of these drugs in combination exceeded the effect each had on controlling the growth, cellular signaling, and tumor development when administered alone," added Shyhmin Huang, Ph.D., a senior scientist in Harari's laboratory and lead author on the publication.

The anti-EGFR drugs are of two types:

  • The monoclonal antibody Erbitux hits the EGFR high, binding to a specific site on the receptor outside the cell membrane. Erbitux blocks the receptor from responding to extracellular signals that tu
    '"/>


Contact: Russell Vanderboom, PhD
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
1-Aug-2004


Page: 1 2 3

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Smart gene therapy protects against damage from heart attack
3. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack
4. New standard to help diagnose heart attacks
5. Variation of gene associated with decreased risk of heart attack and stroke
6. Dampened hopes for transplanting bone marrow stem cells in heart attacks
7. Protein may help prevent autoimmune attacks
8. Biosensor-regulated gene therapy reduces heart attack damage in mice
9. Lion attacks on livestock in Africa are significant but manageable
10. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
11. Stem-cell therapy could have benefits and risks for heart-attack PTs

Post Your Comments:
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
(Date:9/4/2015)... ... September 04, 2015 , ... ... bioprinter, the BioBot 1, at the 2015 TERMIS World Congress in Boston. The ... and biomedical engineering institutions around the world. The printer is revolutionary for its ...
(Date:9/3/2015)... Sept. 3, 2015  Guardant Health®, the leader ... highlighting the performance and clinical utility of Guardant360® ... oral and poster presentations at the International Association ... Conference on Lung Cancer. These abstracts were submitted ... California, Davis; the University of Chicago; Sarah Cannon ...
(Date:9/3/2015)... India , September 3, 2015 ... Instruments Market by System (LC (HPLC, UHPLC, Flash), GC, ... Phase Columns, Syringe Filters, Vials) - Analysis & Global ... Market is expected to reach around 9.223 Billion by ... CAGR of 5.5%. Browse 141 tables and ...
(Date:9/2/2015)... Bermuda , Sept. 2, 2015 Axovant Sciences ... the treatment of dementia, today announced upcoming presentations at three ... PM at the Baird 2015 Healthcare Conference in ... , Thursday, September 10 at 2:00 PM at the ... at the Millennium Broadway Hotel & Conference Center , ...
Breaking Biology Technology:BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 2BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 4Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3
Cached News: